Acadia PharmaceuticalsACAD
About: Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Employees: 620
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
151% more call options, than puts
Call options by funds: $16M | Put options by funds: $6.39M
9% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 81
4% less funds holding
Funds holding: 265 [Q2] → 255 (-10) [Q3]
5.75% less ownership
Funds ownership: 99.02% [Q2] → 93.27% (-5.75%) [Q3]
10% less capital invested
Capital invested by funds: $2.66B [Q2] → $2.38B (-$278M) [Q3]
22% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 46
40% less funds holding in top 10
Funds holding in top 10: 5 [Q2] → 3 (-2) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Needham Ami Fadia 54% 1-year accuracy 75 / 138 met price target | 63%upside $28 | Buy Reiterated | 7 Nov 2024 |
HC Wainwright & Co. Andrew Fein 38% 1-year accuracy 42 / 112 met price target | 57%upside $27 | Buy Reiterated | 7 Nov 2024 |
Financial journalist opinion
Based on 13 articles about ACAD published over the past 30 days
